Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

complement factor

3 posts
RRoche
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Read More

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

  • 2026-10-23
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions…
RRoche
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Read More

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

  • 2026-10-01
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions…
RRoche
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Read More

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

  • 2026-09-23
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions…
Switzerland
www.europesays.com